March 2009. Volume 5. Number 1

Montelukast is not effective in reducing the symptoms of post-respiratory syncyitial virus bronchiolitis

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med. 2008;178:854-60
Reviewers: González de Dios J1, Ochoa Sangrador C2.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 10/01/2009
Acceptance date: 12/01/2009
Publication date: 15/01/2009

Abstract

Authors' conclusions: montelukast did not improve respiratory symptoms of post-RSV bronchiolitis in children.

Reviewers' comantary: this clinical trial contradicts a previous pilot study with methodological limitations. Montelukast has not proven to be effective in respiratory symptoms post-RSV bronchiolitis and there are doubts about its efficacy in severe bronchiolitis with persistent symptoms in the first two weeks.

How to cite this article

González de Dios J, Ochoa Sangrador C. Montelukast no es eficaz como tratamiento preventivo en la enfermedad reactiva de las vías aéreas postbronquiolitis. Evid Pediatr. 2009;5:4.

AVC | Critically appraised articles

Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med. 2008;178:854-60
Reviewers: González de Dios J1, Ochoa Sangrador C2.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 10/01/2009
Acceptance date: 12/01/2009
Publication date: 15/01/2009

How to cite this article

González de Dios J, Ochoa Sangrador C. Montelukast no es eficaz como tratamiento preventivo en la enfermedad reactiva de las vías aéreas postbronquiolitis. Evid Pediatr. 2009;5:4.

References

  1. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J. 2003;22:S76-82.
  2. Dakhama A, Lee YM, Gelfand EW. Virus-induced airway dysfunction: pathogenesis and biomechanisms. Pediatr Infect Dis J. 2005;24:S159-69.
  3. Bisgaard H; Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med. 2003;167:379-83.
  4. Buñuel Álvarez JC. Actualmente no hay pruebas que apoyen la eficacia del montelukast en el tratamiento de la bronquiolitis aguda leve en atención primaria. Evid Pediatr. 2008;4:20.
15/01/2009

Linked Comment